Gene expression analysis in ER-positive breast cancer patients showed that blocking the liganded ER activation with aromatase inhibitor (letrozole) continuously increased the tumor infiltration with B cell and T helper lymphocyte subsets following treatment initiation [158]. Here, CYP19A1 is linked to breast carcinoma.